Restoring Calm,
Reclaiming Lives
Transforming the treatment of PTSD through expert-driven bioelectronic innovation
Post-traumatic stress disorder represents one of the most significant unmet medical needs globally, affecting millions while treatment options remain limited.
The PTSD Crisis
24M
ADULTS AFFECTED (EU+US)
50%
TREATMENT-RESISTANT DESPITE STANDARD CARE
$350B
GLOBAL SOCIETAL COST ANNUALLY
3X
INCREASED OPIOD DEPENDENCY RISK
Understanding PTSD Burden
Clinical Manifestation: Intrusive memories, nightmares, hyperarousal, avoidance behaviors, and emotional dysregulation persist despite current gold-standard therapies including SSRIs and trauma-focused psychotherapy.
Neurobiological Reality: PTSD is fundamentally a dysregulation of the autonomic nervous system, where the body's "fight-or-flight" response remains locked in an activated state long after threat has passed.
Economic & Human Cost: Beyond healthcare expenses, PTSD drives disability, lost productivity, increased opioid utilization, and tragically, elevated suicide risk (+22%).
Military Population: Service members face 2–8× higher prevalence than civilians, with lasting impact on readiness, retention, and long-term health.
A New Paradigm in PTSD Treatment
A first-in-class therapy that addresses PTSD at its source — not just the symptoms.
Our Solution
Stimalia is developing a minimally invasive, drug-free approach that targets the autonomic nervous system directly — calming the body's stress response where it originates.
Why It Works
Built on decades of clinical research showing 70–80% of patients experience meaningful relief when the sympathetic “alarm system” is addressed at its source.
What Makes Us Different.
One outpatient procedure — no daily pills, no repeat injections
Drug-free — no systemic side effects
Personalized — tailored to each patient's needs
Durable — designed for long-term benefit
Leadership and Expertise
A team of seasoned neuromodulation, medical device, and clinical experts dedicated to solving the PTSD crisis.
-
CEO & Co-Founder
25+ years of MedTech leadership in neuromodulation, minimally invasive surgery, and digital health. Founded MONA.health (AI in ophthalmology). Former CEO at Man&Science. Drives strategy, fundraising, and commercial partnerships.
-
CTO & Co-Founder
25+ years pioneering neurostimulation R&D; co-inventor on 300+ patent claims. Co-founder and CTO at Synergia Medical. Oversees device architecture, miniaturization, and regulatory engineering.
-
CC & Co-Founder
25+ years in neurovascular and cardiovascular innovation (Boston Scientific, Edwards LifeSciences, Stryker, Penumbra). Drives clinical affairs, key opinion leader relationships, and scientific communication.
PTSD Insights & Research
Thought leadership on the neurobiological basis of PTSD, clinical evidence, and the future of trauma-informed care.
Get In Touch
Interested in partnership, investment, or collaboration? Let's talk about the future of PTSD treatment.